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Exposure to stress elicits excitoxicity and neuroinflammation in the brain, contributing to cell death and damage in stress-related
neurological and neuropsychiatric diseases. The endocannabinoid system is present in stress-responsive neural circuits and has been
proposed as an endogenous neuroprotective system activated in some neuropathological scenarios to restore homeostasis. To elucidate
the possible regulatory role of cannabinoid receptor 1 (CB1) in stress-induced excitotoxicity and neuroinflammation, both genetic and
pharmacological approaches were used alternatively: (1) wild-type (WT) and CB1 knockout mice (CB1-KO) were exposed to
immobilization/acoustic stress (2 h/day for 4 days) and (2) to specifically activate CB1, the selective CB1 agonist Arachidonyl-20-
chloroethylamide (ACEA) (2.5 mg/kg) was intraperitoneally administered daily to some groups of animals. Stress exposure increased CB1
mRNA and protein expression in the prefrontal cortex of WT mice in a mechanism related to N-methyl-D-aspartate glutamate receptor
activation. Daily ACEA pretreatment prevented stress-induced: (1) upregulation of CB1 mRNA and protein, (2) decrease in glutamate
uptake and glutamate astroglial transporter excitatory amino acid transporter 2 expression, (3) increase in consecutive proinflammatory
molecules, such as cytokines (tumor necrosis factor-a and MCP-1), nuclear factor kappa B, and enzymatic sources, such as inducible nitric
oxide synthase (NOS-2) and cyclooxygenase-2 (COX-2), (4) increase in lipid peroxidation; although having no effect on plasma
corticosterone. Interestingly, a possible related mechanism could be the positive ACEA modulation of the antiinflammatory pathway
deoxyprostaglandin/peroxisome proliferator-activated receptor g (15d-PGJ2/PPARg). Conversely, KO animal experiments indicated
that a lack of CB1 produces hypothalamic/pituitary/adrenal (HPA) axis dysregulation and exacerbates stress-induced excitotoxic/
neuroinflammatory responses. These multifaceted neuroprotective effects suggest that CB1 activation could be a new therapeutic
strategy against neurological/neuropsychiatric pathologies with HPA axis dysregulation and an excitotoxic/neuroinflammatory
component in their pathophysiology.
Neuropsychopharmacology (2011) 36, 805–818; doi:10.1038/npp.2010.214; published online 8 December 2010
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INTRODUCTION
Uncontrolled excitotoxicity and neuroinflammation contri-
bute to cell death and damage in neurological and
neuropsychiatric diseases, including some that are related
to stress exposure (neurodegenerative diseases, depression,
post-traumatic stress disorder, and schizophrenia) (McLeod
et al, 2001; Madrigal et al, 2006). Indeed, previous studies
indicate that long-lasting stress affects synaptic plasticity,
dendritic morphology, and neurogenesis in animals
(reviewed in Kim and Yoon, 1998), and induces both
clinical and anatomical features of neurotoxic damage in
humans (Bremner et al, 1995). Moreover, the relationship
between stressful events and the onset, evolution, and
resolution of inflammatory-related diseases (cardiovascular,
neurological, digestive, or immunological) is well docu-
mented (Baum and Posluszny, 1999; Slimmer et al, 2001).
The precise molecular and cellular events induced by stress
that are responsible for the brain damage found in these
conditions are still a matter of debate. In this way, previous
studies using stress models (physical, psychological, or
mixed) reported a consistent brain response that is mainly
characterized by excitotoxicity and a resulting activation of
several consecutive inflammatory mediators (Garcı´a-Bueno
et al, 2008a). Briefly, stress exposure elicits excitotoxicity
due to the massive release of the excitatory amino acid,
glutamate, in some brain areas (eg, the prefrontal cortex)
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(Moghaddam, 1993), inducing the release of proinflamma-
tory cytokines such as tumor necrosis factor-a (TNF-a) or
interleukin 1b (Madrigal et al, 2002). Stress also activates
the nuclear transcription factor-kappa B (NF-kB) pathway
in a TNF-a-dependent mechanism (Bierhaus et al, 2003;
Madrigal et al, 2002). NF-kB activation elicits the expression
and activity of proinflammatory enzymatic sources, such as
inducible nitric oxide (NO) synthase (NOS-2), and cyclo-
oxygenase-2 (COX-2), among others (Madrigal et al, 2001a,
2003). The result of this sequence of events is the
accumulation of oxidative and nitrosative mediators, which
can attack membrane phospholipids and cause cell damage
in a process known as lipid peroxidation (McEwen, 1998;
Madrigal et al, 2001b) (see Figure 9 for a schematic view of
this stress-activated proinflammatory pathway). However,
there remain unresolved issues concerning the mechanisms,
regulation, and functional significance of the excitotoxic/
inflammatory processes induced by stress in the brain.
In spite of stress-induced production and accumulation
of potentially cytotoxic and/or proinflammatory mediators
like glutamate, NO, peroxynitrite anion (ONOO), or
prostaglandin E2 (PGE2), various authors have discussed
the possibility that some of the many changes caused by
stress response effectors are not damaging to the neurons,
but in fact predominantly beneficial to their structure
and function (McEwen, 1998). One possible mechanism
involved as a possible neuroprotective pathway that has
received considerable experimental attention is led by some
COX-2-derived lipid mediators, such as prostaglandin
15d-PGJ2 and its peroxisome proliferator-activated nuclear
receptor g (PPARg). This COX-derived sub-pathway is
activated in the brain in response to stress and other
neuroinflammatory stimuli, constituting a possible endo-
genous antiinflammatory defense mechanism against
excessive excitotoxicity and neuroinflammation (Garcı´a-
Bueno et al, 2008a) (see Figure 8 for a schematic view of this
stress-activated antiinflammatory pathway).
The study of alternative/related antiinflammatory pathways
deserves further attention to understand pathophysiological
inflammatory alterations as well as to develop possible new
therapeutic approaches for the treatment of stress-related
neuropathologies. Currently, the endocannabinoid system
(ECS) is considered as an endogenous homeostatic system
activated by different immune challenges, restoring brain
balance at different levels (Mechoulam and Shohami, 2007)
in different experimental settings (Galve-Roperh et al,
2008; Wolf et al, 2008; Bambico et al, 2009; Cabral and
Griffin-Thomas, 2009). ECS refers to a group of endogenous
arachidonate-based lipids (ie, anandamide and 2-arachido-
noylglycerol), widely known as ‘endocannabinoids’; their
cannabinoid G protein-coupled receptors, namely cannabi-
noid receptor 1 (CB1) and CB2, and the enzymes fatty acid
amide hydrolase and monoacylglycerol lipase that are
responsible for their degradation and/or reuptake.
Interestingly, several epidemiological studies have identi-
fied that cannabinoids affect anxiety and stress respon-
sivity (Ledent et al, 1999), and the presence of the ECS in
stress-responsive neural circuits suggests that it may have a
critical role in regulating hypothalamic/pituitary/adrenal
(HPA) axis activation and the resulting excitotoxic/neuro-
inflammatory response. Although it is widely assumed
that this response is mainly mediated by the CB2 receptor,
which is expressed by a wide range of immune cells
(Are´valo-Martı´n et al, 2003), recent evidence suggests that
pharmacological enhancement of CB1 protects neurons
from acute brain injury, demonstrating a potentially attrac-
tive alternative therapeutic strategy against CNS pathologies
that deserves further investigation (Cabral and Griffin-
Thomas, 2009).
Taking into account all this background, the aim of the
present study was to explore the effect of sub-chronic stress
exposure on CB1 expression in the prefrontal cortex in
mice, and the possible regulatory role of CB1 in conditions
of stress-induced excitotoxicity and neuroinflammation,
using alternatively pharmacological (activation of CB1
with the selective agonist arachidonyl-20-chloroethylamide
(ACEA)) and genetic (CB1 receptor-deficient mice) strategies.
MATERIALS AND METHODS
Animals
Adult male CB1 double mutant CB1 (/) mice and wild-
type CB1 (WT) littermates (ICR (Swiss) strain) were used in
all the experiments. The generation of mice lacking the CB1
receptor has been described previously (Ledent et al, 1999).
WT and CB1 (/) mice used in a given experiment,
originated from the same breeding series and were matched
for age and weight (age¼ 2–3 months; weight¼ 25–30 g).
All experimental protocols adhered to the guidelines of the
animal welfare committee of the Universidad Complutense
in accordance with European legislation (DC 86/609/CEE).
The mice were housed individually with standard tempera-
ture and humidity conditions and in a 12-h light/dark cycle
(lights on at 0800 h) with free access to food and water.
All the animals were maintained under constant conditions
for 4 days before the exposure to stress.
Stress Protocol
Mice were exposed to sub-chronic immobilization and
acoustic stress using an ultrasound bath (2 h from 1300 h to
1500h for 4 days) as previously described (Kiank et al, 2006;
Depke et al, 2008; Olfe et al, 2010). The restraint/acoustic
stress model is classified as both physical and psychological,
predictable, and inescapable, suitable for studying the
neurochemical effects of stress on brain function. Some
authors have evaluated restraint and acoustic stress, both
separately and in combination, and found that larger and
more predictable responses were obtained with the
combined stressors (Qiu et al, 1999). Stressed animals were
put down immediately after the restraint (while still in the
restrainer) using sodium pentobarbital (320mg/kg i.p.).
Control animals were not submitted to stress but were
handled at 1300 h for a few seconds, and food and water
were removed. They were put down at the same time as the
stressed animals (1500 h). Blood for plasma determinations
was collected by cardiac puncture and anticoagulated in the
presence of trisodium citrate (3.15% (wt/vol), 1 vol citrate
per 9 vol blood). After decapitation, the brain was removed
from the skull, and after careful removal of the meninges
and blood vessels, the prefrontal cortical areas from both
brain hemispheres were excised and frozen at 801C until
assayed. Mouse brain prefrontal cortex was chosen because
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of its high levels of CB1 receptor, proinflammatory (NOS-2,
prostaglandin E2), and antiinflammatory (PPARg, lipocalin
prostaglandin D synthase) mediators, its susceptibility to
excitotoxic/neuroinflammatory process elicited by inflam-
matory/immune stimulus (Garcı´a-Bueno et al, 2008b), and
finally because this brain area is an important neural
substrate for the regulation of the HPA axis response to
stress (Radley et al, 2006).
Pharmacological Tools
Various groups of animals were injected with the potent
and highly selective CB1 receptor agonist (Ki¼ 1.4 nM;
41400-fold CB1 selectivity over CB2) ACEA, using a dose
of 2.5mg/kg administered intraperitoneally (i.p.) daily or its
vehicle (a solution of 5% ethanol, 5% dextrose, and 5%
Tween 80 in sterile saline). The dose of ACEA was used
based on preceding studies in neuroinflammation-related
models (Are´valo-Martı´n et al, 2003). To block N-methyl-D-
aspartate (NMDA) glutamate receptor-dependent effects,
two groups of animals were i.p. injected with dizocilpine
[( + )-5-methyl-10,11-dihydroxy-5H-dibenzo (a, d) cyclo-
hepten-5,10-imine; MK-801], a specific noncompetitive
NMDA antagonist (MK; 0.1mg/kg). This low dose was
chosen to avoid possible neurotoxic, hallucinogenic, and
HPA axis disturbing effects from this compound when it
is used at higher doses, and was based on preceding
studies from our laboratory and others (Garcı´a-Bueno et al,
2008b; Jezova et al, 1995). ACEA and vehicle were injected
at the onset of the stress (1300 h), and MK-801 and its
vehicle (saline) were respectively i.p. injected 1 h before the
onset of the stress (1200 h). None of the parameters studied
were modified in the two different vehicle-treated groups
of mice when compared with the noninjected animals.
To simplify figures, both groups were unified into one
vehicle-injected group in control (CWT) and stress (SWT)
conditions. Each experimental group included at least six
animals.
Preparation of Cytosolic and Nuclear Extracts
A modified procedure based on the method of Schreiber
et al (1989) was used. Tissues (cerebral cortex) were
homogenized with 300 ml of buffer (10mmol/l N-2-hydroxy-
ethylpiperazine-N0-2-ethanesulfonic acid, pH 7.9; 1mmol/l
ethylenediamine tetraacetic acid (EDTA), 1mmol/l EGTA,
10mmol/l KCl, 1mmol/l DTT), 0.5mmol/l phenylmethyl-
sulfonyl fluoride, 0.1 mg/ml aprotinin, 1 mg/ml leupeptin,
1 mg/ml Na-p-tosyl-L-lysine-chloromethyl ketone, 5mmol/l
NaF, 1mmol/l NaVO4, 0.5mol/l sucrose, and 10mmol/l
Na2MoO4). After 15min, Nonidet P-40 (Roche) was added
to a 0.5% concentration level. The tubes were gently
vortexed for 15 s, and nuclei were collected by centrifuga-
tion at 8000 g for 5min. Supernatants were taken as a
cytosolic fraction. The pellets were resuspended in 100 ml
of buffer supplemented with 20% glycerol and 0.4mol/l
KCl, and gently shaken for 30min at 4 1C. Nuclear protein
extracts were obtained by centrifugation at 13 000 g for
5min, and aliquots of the supernatant were stored at 801C.
All steps of the fractionation were carried out at 41C.
Western Blot Analysis
After determining and adjusting protein levels, homoge-
nates of prefrontal cortex tissue, once centrifuged (12000 g,
20min at 41C) were mixed with Laemmli sample buffer
(Bio-Rad, Hercules, CA) (SDS 10%, distilled H2O, 50%
glycerol, 1M Tris HCl, pH 6.8, dithiothreitol, and blue
bromophenol) with beta mercaptoethanol (50 ml/ml of
Laemmli) and 20 ml (2 mg/ml) were loaded into an electro-
phoresis gel. Once separated on the basis of molecular
weight, proteins from the gels were blotted onto a
polyvinylidene difluoride membrane (Millipore, Bedford,
MA) or nitrocellulose membrane (Amersham Ibe´rica,
Spain) with a semi-dry transfer system (Bio-Rad) and were
incubated with specific antibodies: (1) rabbit polyclonal
CB1, raised against the synthetic peptide MSVSTDTSAEAL,
corresponding to C-terminal amino acids 461–472 of
human CB1 in a dilution of 1 : 1000 in 5% bovine serum
albumin (BSA) in TBS-Tween (Abcam, Cambridge, UK);
(2) rabbit polyclonal excitatory amino acid transporter 2
(EAAT-2) raised against an epitope corresponding to amino
acids 1–85 mapping at the N-terminus of EAAT-2 of human
origin in a dilution of 1 : 1000 in 5% BSA in TBS-Tween
(sc-15317) (Santa Cruz Biotechnology, CA); (3) specific
rabbit polyclonal PPARg (epitope corresponding to amino
acids 8–106 mapping at the N-terminus of PPARg1 of
human origin) in a dilution of 1 : 1000 in 5% BSA in TBS-
Tween (sc-7196) (Santa Cruz Biotechnology); (4) rabbit
polyclonal IkBa (epitope mapping at the C-terminus of
IkB-a of human origin) in a dilution of 1 : 1000 in 5%
skimmed milk in BSA (Santa Cruz Biotechnology) (5) rabbit
polyclonal NF-kB p65 (epitope mapping within the
N-terminus of NFkB p65 of human origin) in a dilution of
1 : 500 in BSA 2% (sc-109) (Santa Cruz Biotechnology);
(6) NOS-2 rabbit polyclonal antibody from Santa Cruz
Biotechnology raised against a peptide mapping at the
amino terminus of NOS-2 of human origin in a dilution of
1 : 1000 in TBS-Tween (sc-651); (7) COX-2 goat polyclonal
antibody from Santa Cruz Biotechnology raised against a
peptide mapping at the C-terminus of COX-2 of human
origin in a dilution of 1 : 750 in 5% BSA in TBS-Tween
(sc-1745); (8) L-PGDS rabbit polyclonal antibody,
which recognizes human L-PGDS amino acids 30–41
(VQPNFQPDKFLG) in a dilution of 1 : 500 in 5% BSA in
TBS-Tween (Cayman Chemical Europe, Tallinn, Estonia).
Proteins recognized by the respective horseradish perox-
idase-linked secondary antibodies (in a dilution of 1 : 1000
in 2–5% BSA in TBS-Tween) and visualized on X-ray film
by chemiluminescence following manufacturer’s instruc-
tions (Amersham). Autoradiographs were quantified by
densitometry (program Image J, NIH), and several time
expositions were analyzed to ensure the linearity of the
band intensities. All densitometries are expressed in
arbitrary units (AU). In all the WB analyses, the house-
keeping gene b-actin was used as a loading control (the
blots are shown in the respective figures).
mRNA Analysis
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen, Barcelona, Spain); aliquots were converted
to cDNA using random hexamer primers. Quantitative
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changes in mRNA levels were estimated by real-time PCR
(Q-PCR) using the following cycling conditions: 35 cycles of
denaturation at 951C for 10 s, annealing at 58–611C for 15 s,
depending on the specific set of primers, and extension at
721C for 20 s. Reactions were carried out in the presence of
SYBR green (1 : 10 000 dilution of stock solution from
Molecular Probes, Eugene, OR), carried out in a 20-ml
reaction in a Corbett Rotor-Gene (Corbett Research,
Mortlake, NSW, Australia).
The primers used for CB1 were: forward 50-AACTGTGCC
AGGCAATCTGTTGTG-30 and reverse 50-GGCCTTCCCATT
GAAGCACAAACT-30; for TNF-a: forward ACCACTCTCCC
TTTGCAGAACTCA and reverse TCTCATGCACCACCATC
AAGGACT; and for tubulin were: forward 50-CCCTCGCC
ATGGTAAATACAT-30 and reverse 50-ACTGGATGGTACGC
TTGGTCT-30. Relative mRNA concentrations were calcu-
lated from the take-off point of reactions using the included
software, and tubulin levels were used to normalize data.
Preparation of Synaptosomes
After decapitation, half of the forebrain was dissected on
ice. All subsequent steps were performed at 41C. Cortical
tissue was immediately homogenized in 25 vols of 0.32M
sucrose in a glass homogenizer fitted with a Teflon pestle.
The homogenate was centrifuged at 200 g for 10min, and
the supernatant was then collected and centrifuged at
20 000 g for 20min. The pellet was resuspended in 0.32M
sucrose and centrifuged at 20 000 g for 20min. The crude
synaptosomal pellet was finally resuspended in 1ml of
0.32M sucrose. Synaptosomal preparations, consisting of
pre- and post-synaptic elements of neurons and associated
astrocytic endfeet, have provided insights into the regula-
tion of a variety of synaptic functions, including neuro-
transmitter release and reuptake, energy metabolism, and
ion transport systems in physiological, neurological, and
neurodegenerative disorders (Begley et al, 1998).
[3H]Glutamate Uptake by Synaptosomes
Sodium-dependent glutamate uptake in synaptosomes was
measured according to the procedure previously described
by Robinson et al (1991) with some modifications. In brief,
25-ml aliquots of synaptosomes were added to 250ml of
incubation buffer (5mM Tris, 10mM HEPES, 2.5mM KCl,
1.4M NaCl, 1.2mM CaCl2, 1.2mM MgCl2, 1.2mM KH2PO4,
and 10mM dextrose, pH 7.4) containing L-[3H]glutamic
acid 0.125mM (1mCi/ml; Amersham Biosciences Europe
GmbH, Freiburg, Germany) and incubated for 3min at 371C
in a shaking waterbath. The reaction was terminated using
1ml of ice-cold choline buffer (an incubation buffer in
which an equimolar concentration of choline chloride was
substituted for NaCl), and the samples were centrifuged
at 10 000 g for 2min to recover the synaptosomes. The
3H-bound radioactivity was measured using a liquid
scintillation counter.
Plasma Corticosterone Levels
Plasma was obtained from blood samples by centrifuging
them at 1000 g for 15min immediately after the stress
exposure. All plasma samples were stored at 201C before
assay with a commercially available radioimmunoassay kit
(131I-labeled corticosterone; DPC, Los Angeles, CA). A gamma
counter was used to measure radioactivity of the samples. The
values obtained in the control animals (100±34.22 ng/ml)
matched the kit manufacturer’s expected values in adult mice
at the time of blood extraction (approximately 1500 h).
MCP-1 Measurement
MCP-1 levels in the prefrontal cortex homogenates were
detected using a specific ELISA kit for MCP-1, according
to manufacturer’s instructions (R&D systems, Abingdon,
UK). The assay detection limits were 31.3–2000 pg/ml. To
determine tissue levels of MCP-1, brain prefrontal cortices
were removed and homogenized by sonication for 10 s at
41C in PBS containing complete protease inhibitor cocktail
(Roche Diagnostics). The homogenates were centrifuged
(13 000 g, 10min, 41C), and supernatants were used for
determinations using the ELISA kit. Protein content was
determined by Bradford’s method using BSA as standard.
Lipid Peroxidation
Lipid peroxidation was measured by the thiobarbituric acid
test for malondialdehyde (MDA) following the method
described by Das and Ratty (1987) with some modifications.
Cerebral cortex was sonicated in 10 vol of 50mmol/l
phosphate buffer and deproteinized with 40% trichloro-
acetic acid and 5mol/l HCl, followed by the addition of 2%
(wt/vol) thiobarbituric acid in 0.5mol/l NaOH. The reaction
mixture was heated in a waterbath at 901C for 15min and
centrifuged at 12 000 g for 10min. The pink chromogen was
measured at 532 nm in a Beckman DU-7500 spectro-
photometer (Beckman). The results were expressed as
nmol/mg of protein.
Brain PGE2 and 15d-PGJ2 Levels
PGE2 and 15d-PGJ2 brain levels were measured by
enzyme immunoassay (EIA) using reagents in kit form
(Prostaglandin E2 EIA Kit-Monoclonal; (Cayman Chemical)
and 15-deoxy-D12,14-prostaglandin J2 ELISA Kit (DRG
Diagnostics, Marburg, Germany), respectively. Samples
were sonicated in 300 ml homogenization buffer (0.1M
phosphate buffer, pH, 7.4, 1mM EDTA, and 10 mM indo-
methacin) and purified by incubation in ethanol at 4
sample volume for 5min at 41C, and then centrifugation at
3000 g for 10min. They were acidified with glacial acetic
acid to pH 3.5, and PGE2 was extracted using SPE (C-18)
columns (Amersham Biosciences, Buckinghamshire, UK)
rinsed with methanol and water. After the application
of samples, columns were washed with water and hexane,
and PGE2 and 15d-PGJ2 were eluted with ethyl acetate.
Samples were then evaporated to dryness under nitrogen
and resuspended in EIA buffer. Levels of PGE2 and 15d-
PGJ2 were measured in a 96-well plate and read at 405 nm
following manufacturer’s instructions. The sensitivity of the
assay for PGE2 was 15 pg/ml; intra- and interassay coeffi-
cients of variation were 6.6 and 15.5%, respectively, at
62.5 pg/ml, and for 15d-PGJ2 the sensitivity was 36.8 pg/ml;
intra- and interassay coefficient of variations were 7.4 and
13%, respectively, at 4.4 pg/ml.
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Protein Assay
Protein levels were measured using Bradford method based
on the principle of protein-dye binding (Bradford, 1976).
Chemicals and Statistical Analyses
Unless otherwise stated, the chemicals were from Sigma
Spain, Madrid. Data in text and figures are expressed
as mean ± SEM. For multiple comparisons, a one-way
ANOVA followed by the Newman–Keuls post hoc test
to compare all pairs of means between groups was made.
A p-value o0.05 was considered statistically significant.
RESULTS
CB1 Expression in the Prefrontal Cortex of Control and
Stressed WT Mice. Glutamate-Related Mechanism
Our first study was aimed to elucidate the possible effect of
stress exposure on CB1 expression in the prefrontal cortex
in mice. Western blot studies and subsequent densitometric
analysis of the band of interest (Figure 1a) revealed a
significant increase in CB1 protein expression (E60 kDa
band) elicited by stress. As expected, this band is absent in
CB1 knockout (KO) mice in control and stress conditions,
validating the specificity of the antibody used. This observed
increase in protein expression is in agreement with CB1
mRNA upregulation, quantified by Q-PCR (Figure 1b).
Prestress daily ACEA administration blocked stress-
induced CB1 mRNA upregulation (Figure 1b) and protein
expression (Figure 1c) in the prefrontal cortex in mice. In
control conditions, neither ACEA nor MK treatments were
able to modify CB1 protein and mRNA expression (data not
shown to simplify Figures 1b and c).
Stress exposure leads to the massive release of glutamate
into the synaptic cleft, reaching excitotoxic levels in some
brain areas (ie, hippocampus, prefrontal cortex) (Moghaddam,
1993). To elucidate whether stress-induced CB1 upregulation is
related to this massive glutamate release, a group of animals
was i.p. injected with the NMDA-selective blocker, MK-801, at
1 h before the onset of the stress exposure. Interestingly, daily
administration of MK-801 partly inhibited stress-induced CB1
mRNA upregulation (Figure 1b) and protein overexpression
(Figure 1c) in the prefrontal cortex of WT mice.
CB1-Dependent Effects on Stress-Induced Changes in
Synaptosomal Glutamate Uptake and Expression of
Glutamate Transporters
The ECS has been shown to confer neuroprotection
inhibiting glutamatergic excitotoxic neurotransmission by
mechanism/s still not completely understood. We decided
to explore the possible effects of CB1 on glutamate transport
in brain cortical synaptosomes from WT and CB1 KO mice
submitted to stress.
Figure 1 CB1 upregulation is elicited by stress exposure in mouse prefrontal cortex in a glutamate-related mechanism. (a) Western blot and
densitometric analysis of CB1 band in the prefrontal cortex of control (CWT) and stressed during 4 days (SWT) wild-type mice, and control (CKO) and
stressed (SKO) CB1 KO mice. The densitometric data are normalized by b-actin (lower band) and are representative of three experiments. *po0.05 vs
CWT (one-way ANOVA followed by Newman–Keuls post hoc test). AU: arbitrary units. (b) Q-PCR analysis of CB1 mRNA in the prefrontal cortex of
control (CWT), stressed during 4 days (SWT), stressed + ACEA (SWT + ACEA), and stressed + MK-801 (SWT + MK) wild-type mice. Data are
normalized by tubulin, and are representative of three experiments. *po0.05 vs CWT; #po0.05 vs SWT (one-way ANOVA followed by Newman–Keuls
post hoc test. AU, arbitrary units. (c) Western blot and densitometric analysis of CB1 band in the prefrontal cortex of control (CWT), stressed during 4 days
(SWT), stressed + ACEA (SWT + ACEA), and stressed + MK-801 (SWT + MK) wild-type mice. Data are normalized by b-actin and are representative
of three experiments. *po0.05 vs CWT; #po0.05 vs SWT (one-way ANOVA followed by Newman–Keuls post hoc test). AU, arbitrary units.
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As it has been previously described (Garcı´a-Bueno et al,
2007), stress exposure leads to a marked decrease in
glutamate uptake compared with what was seen in the control
group (Figure 2a). Pretreatment with ACEA fully prevented
this stress-induced impairment in glutamate uptake function
(Figure 2a). Conversely, CB1 KO mice showed dramatically
reduced glutamate transport in cortical synaptosomes in both
control and stress conditions (Figure 2a).
We also assessed the possibility that these effects might be
due to expressional changes in the main brain glutamate
transporter, EAAT-2 (astrocytic). Western blot analysis
revealed that stress exposure reduced EAAT-2 expression
(Figure 2b), and that treatment with ACEA prevented this
stress-induced decrease. As in the case of synaptosomal
glutamate transport, both stressed and nonstressed CB1 KO
mice showed reduced EAAT-2 expression in brain cortical
homogenates (Figure 2b).
Antiinflammatory Effects Elicited by CB1 Activation.
Mechanisms Involved
In general, ECS has been proposed as an endogenous
protective system against excessive inflammatory/immune
responses in multiple CNS pathologies. Our following
studies were aimed at clarifying the particular role of
CB1 as a possible regulator of stress-induced inflammatory
response.
Effects on HPA axis activity. Plasma corticosterone levels.
Our first study evaluated CB1 effects on glucocorticoid
synthesis, the main stress hormones, widely known as
classical regulators of the inflammatory/immune response
in brain and periphery.
The quantification by RIA of plasma corticosterone
levels at the time of blood extraction (approximately
1500 h) in all groups studied revealed an expected increase
in corticosterone in all groups of stressed animals compared
with their respective controls (Figure 3); however, this
increase is statistically higher in KO mice than in WT
animals (Figure 3). Interestingly, daily ACEA administra-
tion did not change plasma corticosterone levels after stress
at the time of blood extraction (Figure 3), suggesting that
the mechanism(s) of this compound in modulating stress
response could be independent of peripheral corticosterone
levels.
Figure 2 CB1 effects on synaptosomal glutamate uptake and transporters. (a) Glutamate uptake in forebrain synaptosomes of control (CWT), control +
ACEA (CWT + ACEA), stressed during 4 days (SWT), and stressed + ACEA (SWT + ACEA) wild-type mice, and control (CKO) and stressed (SKO)
CB1 KO mice. The data represents the mean± SEM of six mice. *po0.05 vs CWT; #po0.05 vs SWT (one-way ANOVA followed by Newman–Keuls post
hoc test). (b) Western blot and densitometric analysis of glial glutamate transporter EAAT-2 band in the prefrontal cortex of control (CWT), control + daily
ACEA (CWT + ACEA), stressed during 4 days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice, and control (CKO) and stressed
(SKO) CB1 KO mice. Data are normalized by b-actin (lower band), and are representative of three experiments. *po0.05 vs CWT; #po0.05 vs SWT (one-
way ANOVA followed by Newman–Keuls post hoc test). AU, arbitrary units.
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Brain proinflammatory cytokines and chemokines. Proin-
flammatory cytokines, such as TNF-a or MCP-1, are the first
proinflammatory mediators activated in the brain by the
massive release of glutamate after stress exposure. Q-PCR
studies showed a consistent increase in TNF-a mRNA in
WT mouse prefrontal cortex after stress, an effect that is
blocked by ACEA (Figure 4a). Conversely, stressed CB1 KO
animals presented a reliable increase in the mRNA of the
proinflammatory cytokine, suggesting a potentially deleter-
ious chronic inflammatory status in brain. Stress also
increased MCP-1 levels in the prefrontal cortex of WT mice
and pharmacological stimulation of CB1 decreased them.
CB1 KO mice showed no differences from WT in
nonstressed animals. However, stress increased MCP-1
levels in brain in SKO group compared with SWT group
(Figure 4b).
In this set of neuroinflammation-related experiments
(Figures 4–7) there were no differences between CWT and
CWT + ACEA groups and the data are not shown to
simplify figures.
Nuclear factor-kB. The release of TNF-a after stress also
accounts for NF-kB activation, and we also tested the
possible involvement of CB1 in the level of NF-kB expression.
Western blot studies of the inhibitory protein of NF-kB
(IkBa) in cytosolic extracts (Figure 5a) and proinflamma-
tory NFkB subunit (p65) in nuclear extracts (Figure 5b)
revealed that CB1 regulated NF-kB activation after stress. As
it can be observed, stress exposure induced a decrease in the
expression of IkBa in brain extracts from WT mice, which
was reversed by ACEA (Figure 5a). Levels of nuclear p65 in
the different groups studied (Figure 5b) mirrored the
expression of its inhibitory factor. CB1 KO animals presented
lower levels of IkBa in cytosolic extracts than their respective
controls (CWT) (Figure 5a) and a consequent increase in p65
protein in nuclear extracts (Figure 5b), suggesting a state of
chronic NF-kB activation in these animals. Interestingly,
stress exposure did not affect IkBa/NF-kB expression in the
prefrontal cortex of CB1 KO mice.
Proinflammatory enzymes (NOS-2 and COX-2). NF-kB
regulates the expression of genes involved in the accumula-
tion of oxidative/nitrosative and inflammatory mediators
after stress exposure. Among others, two main sources of
these mediators dependent on NF-kB are inducible NOS-2
Figure 3 CB1-related effects on plasma corticosterone levels. Corticosterone plasma levels (ng/ml) at the time of blood extraction (1500 h) of control
(CWT), control + daily ACEA (CWT + ACEA), stressed during 4 days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice, and control
(CKO) and stressed (SKO) CB1 KO mice. Data represents the mean± SEM of six mice. *po0.05 vs CWT; #po0.05 vs SWT; &po0.05 vs CKO (one-way
ANOVA followed by Newman–Keuls post hoc test).
Figure 4 CB1 antiinflammatory effects on brain I. Proinflammatory
cytokines and chemokines. (a) Q-PCR analysis of the proinflammatory
cytokine TNF-a mRNA in the prefrontal cortex of control (CWT), stressed
during 4 days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-
type mice, and control (CKO) and stressed (SKO) CB1 KO mice. Data are
normalized by tubulin, and are representative of three experiments.
*po0.05 vs CWT; #po0.05 vs SWT (one-way ANOVA followed by
Newman–Keuls post hoc test). AU, arbitrary units. (b) MCP-1 levels (pg/mg
protein) in prefrontal cortex homogenates of control (CWT), stressed
during 4 days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-
type mice, and control (CKO) and stressed (SKO) CB1 KO mice. Data
represents the mean ± SEM of six mice. *po0.05 vs CWT; #po0.05 vs
SWT; &po0.05 vs CKO (one-way ANOVA followed by Newman–Keuls
post hoc test).
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and COX-2. Their major products (NO and PGE2, respec-
tively) are potent oxidant/proinflammatory molecules that
have been widely connected with damage and even cellular
death in multiple CNS pathologies. We decided to explore
CB1 effects on the expression and/or activity of these
enzymes.
NOS-2 expression increased in the cerebral cortex after
stress exposure in WT mice (Figure 6a), although no
changes in COX-2 expression were found after this stress
protocol (Figure 6b). However, the presumed brain COX-2-
derived product, PGE2, appeared in an increased quantity
after the stress exposure Figure 6c).
CB1 receptor activation with ACEA was able to com-
pletely block NOS-2 upregulation produced by stress
exposure (Figure 6a). As in the case of other proinflamma-
tory mediators, CB1 KO mice, both in control and stress
conditions, showed consistent NOS-2 upregulation com-
pared with their WT control groups, and a higher increase
after stress (Figure 6a).
The interaction between CB1 receptor and COX-2 is more
complex, as suggested by our results. PGE2 cortical levels, a
presumed COX-2 product in different tissues, including the
brain, are affected by CB1 activation. As it can be observed
in Figure 6c, ACEA reduced PGE2 tissue levels compared
with those in the SWT animals, whereas CB1 SKO animals
presented insignificant differences in PGE2 content com-
pared with the SWT group.
Lipid peroxidation. As a final index of stress-induced
cellular damage that could be affected by CB1-selective
modulation, we measured the accumulation of the lipid
peroxidation marker MDA in the brain prefrontal cortex
of the different groups of mice. Daily treatment with ACEA
prevented MDA overaccumulation, observed after stress
exposure in WT mice (Figure 6d). Conversely, CB1 KO mice
presented higher levels of MDA after stress than the SWT
group (Figure 6d).
CB1-Dependent Modulation of the Antiinflammatory
Pathway L-PGDS/15d-PGJ2/PPARc
So far, our results had shown that the daily administration
of the selective CB1 receptor agonist ACEA prevented
stress-induced excitotoxicity and proinflammatory media-
tor accumulation in the prefrontal cortex of WT mice,
whereas CB1 KO mice presented an aggravated excitotoxic/
neuroinflammatory process after stress exposure. Our final
series of studies were aimed to elucidate possible alternative
antiinflammatory mechanisms related to CB1 activation.
One candidate of interest is the antiinflammatory pathway
L-PGDS/15d-PGJ2/PPARg, that is activated after inflamma-
tory/immune stimuli (stress included) and whose activation
(even by some cannabinoids) has been shown to confer
neuroprotection after stress exposure, and in diverse CNS
pathologies with an inflammatory component in their
pathophysiology.
Western blot studies and subsequent densitometric
analysis (Figure 7a) revealed a significant increase in the
15d-PGJ2 enzymatic source L-PGDS in the prefrontal cortex
homogenates of mouse brains, daily treated with ACEA,
compared with the SWT group. On the other hand, L-PGDS
protein levels were reduced in the brain of CB1 KO mice in
control conditions and after stress exposure (Figure 7a).
Consequently, 15d-PGJ2 levels, quantified by ELISA in
brain prefrontal cortex samples, were increased by the
administration of ACEA in WT mice compared with their
controls (Figure 7b). Both in WT and CB1 KO mice,
stress exposure produced a marked decrease in 15d-PGJ2
levels but there were no differences between WT and KO
animals.
Western blot analysis of PPARg protein revealed a
significant increase of this 15d-PGJ2 nuclear receptor in
prefrontal cortex homogenates of mouse brains, daily
treated with ACEA, compared with their controls after
stress exposure (SWT) (Figure 7c). CKO mice presented
significant lower levels of PPARg than the CWT group, but
stress exposure did not affect PPARg expression in the
brains of CB1 KO animals (Figure 7c).
Figure 5 CB1 antiinflammatory effects on brain II. NF-kB. (a) Western
blot and densitometric analysis of the NF-kB inhibitory protein IkBa in
prefrontal cortex cytosolic extracts of control (CWT), stressed during 4
days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice,
and control (CKO) and stressed (SKO) CB1 KO mice. Data are normalized
by b-actin (lower band), and are representative of three experiments.
*po0.05 vs CWT; #po0.05 vs SWT (one-way ANOVA followed by
Newman–Keuls post hoc test). AU, arbitrary units. (b) Western blot and
densitometric analysis of the NF-kB proinflammatory subunit p65 in
prefrontal cortex nuclear extracts of control (CWT), stressed during 4 days
(SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice, and
control (CKO) and stressed (SKO) CB1 KO mice. Data are normalized by
b-actin (lower band), and are representative of three experiments.
*po0.05 vs CWT; #po0.05 vs SWT (one-way ANOVA followed by
Newman–Keuls post hoc test). AU, arbitrary units.
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Validation of ACEA CB1-Dependent Antiexcitotoxic/
Antiinflammatory Effects
Finally, to elucidate whether ACEA actions are CB1
mediated, we examined its effects in CB1 KO mice on some
representative excitotoxic (EAAT-2 expression) and inflam-
matory parameters (NOS-2 expression and MDA levels)
after sub-chronic stress exposure.
As has been previously shown (Figure 2), stress exposure
downregulates EAAT-2 expression in mouse prefrontal
cortex and this effect is completely prevented by ACEA
pretreatment in WT mice, however this ACEA antiexcito-
toxic effect is absent in CB1 KO mice (SKO + ACEA)
(Figure 8a), suggesting the direct involvement of CB1
receptor. A similar pattern occurs with the proinflammatory
parameter NOS-2 expression (Figure 8b) and MDA levels
(Figure 8c), in which ACEA neuroprotective effects are lost
in CB1 KO mice compared with WT. These results suggest
that ACEA antiinflammatory effects are also dependent on
CB1 in our model.
DISCUSSION
Our studies show for the first time to our knowledge, CB1
upregulation in mouse prefrontal cortex exposed to sub-
chronic restraint/acoustic stress in a mechanism dependent
on NMDA glutamate receptors. In addition, daily ACEA
administration prevented stress-induced upregulation of
CB1 mRNA and protein, and presented an antiexcitotoxic
profile, regulating glutamate transport and uptake
after stress exposure, at least in part by restoring protein
expression of EAAT-2. CB1 activation also produces
antiinflammatory effects, regulating stress-induced proin-
flammatory response at multiple levels. Notably, a possible
related mechanism is the positive modulation of the
Figure 6 CB1 antiinflammatory effects on brain III. Proinflammatory enzymes and lipid peroxidation. (a) Western blot and densitometric analysis of the
proinflammatory enzyme NOS-2 in prefrontal cortex homogenates of control (CWT), stressed during 4 days (SWT), and stressed + daily ACEA (SWT +
ACEA) wild-type mice, and control (CKO) and stressed (SKO) CB1 KO mice. Data are normalized by b-actin (lower band), and are representative of three
experiments. *po0.05 vs CWT; #po0.05 vs SWT (one-way ANOVA followed by Newman–Keuls post hoc test). AU, arbitrary units. (b) COX-2
expression shown by western blot in all groups studied. (c) Proinflammatory PGE2 levels (index of COX-2 activity) in prefrontal cortex homogenates of
control (CWT), stressed during 4 days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice, and control (CKO) and stressed (SKO) CB1
KO mice. Data represents the mean± SEM of six mice. *po0.05 vs CWT; #po0.05 vs SWT; &po0.05 vs CKO (one-way-ANOVA followed by Newman–
Keuls post hoc test). (d) MDA levels in prefrontal cortex homogenates of control (CWT), stressed during 4 days (SWT), and stressed + daily ACEA (SWT
+ ACEA) wild-type mice, and control (CKO) and stressed (SKO) CB1 KO mice. Data represents the mean ± SEM of six mice. *po0.05 vs CWT;
#po0.05 vs SWT; &po0.05 vs CKO (one-way ANOVA followed by Newman–Keuls post hoc test).
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antiinflammatory pathway L-PGDS/15d-PGJ2/PPARg,
although the precise mechanism/s responsible for this
relationship needs to be further investigated (see Figure 9
for a schematic view of the regulatory role of CB1 in stress-
induced excitotoxicity and neuroinflammatory balance).
Stress exposure is a major contributing factor to cell
death and damage in neurological and neuropsychiatric
diseases by three interrelated mechanisms: HPA axis dys-
regulation, excitotoxicity, and neuroinflammation. How-
ever, stress exposure also activates alternative mechanisms
aimed at correctly resolving this response. In this way, the
CB1 upregulation demonstrated here could be a mechanism
related to this protective response of the brain. Similarly,
endocannabinoids are released to negatively regulate HPA
axis activation (Manzanares et al, 1999; Patel et al, 2004),
and brain SEC activation has been considered as a protec-
tive mechanism aimed at reducing both neurodegenerative
and inflammatory damage after an immune/inflammatory
challenge (Centonze et al, 2008).
In particular, our data are in agreement with several
studies that propose a role for CB1 as a main regulator of
glutamate neurotransmission and metabolism in multiple
pathological scenarios (Parmentier-Batteur et al, 2002;
Marsicano et al, 2003; Veldhuis et al, 2003; Ferna´ndez-
Lo´pez et al, 2006; Kim et al, 2006; Gilbert et al, 2007; Lorı´a
et al, 2010). In relation to our findings, stress-induced CB1
upregulation could represent a compensatory response
aimed at controlling the massive release of glutamate into
the synaptic cleft that might produce cellular damage and
even death by excitotoxicity after stress exposure (Lowy
et al, 1993; Stein-Behrens et al, 1994; Garcı´a-Bueno et al,
2007). As reported here, CB1 receptor activation with ACEA
enhances the main glutamate uptake mechanism, by
restoring protein expression of the glutamate transporter
EAAT-2. Astrocyte uptake of glutamate is a high-affinity
process regulated by EAAT-2 (Hertz et al, 1983); the fact
that stress decreases EAAT-2 expression in the cerebral
cortex (Garcı´a-Bueno et al, 2007), indicates a specific
damaging effect at this level, and makes the effect of ACEA
more interesting. CB1 effects on EAAT-2 have also been
demonstrated in other experimental settings, such as an
in vitro model of multiple sclerosis (MS) (Lorı´a et al, 2010),
or after prenatal exposure to WIN 55,212-2 (Castaldo et al,
2007). It has been widely demonstrated that presynaptic
CB1 inhibits glutamate release (Freund et al, 2003;
Chevaleyre et al, 2006; Steiner and Wotjak, 2008), but our
data suggests that glutamatergic neurotransmission is also
regulated by CB1 at the level of postsynaptic reuptake
clearance mechanisms.
How neuronal CB1 activation enhances glutamate glial
uptake may be explained by neuron–actrocyte communica-
tion that regulates PPARg activity in astrocytes. Notably,
EAAT-2 glutamate transporter is a target gene of PPARg
in excitotoxic-related models, such as stress exposure
(Garcı´a-Bueno et al, 2007) or brain ischemia (Romera
et al, 2007). As well, a recent study identified endocanna-
binoids as PPARg agonists affording neuroprotection
targeting EAAT-2 in an in vitro model of MS (Lorı´a et al,
2010).
Regarding stress-induced neuroinflammation, although
cannabinoid-dependent antiinflammatory and antioxidant
actions have been commonly related with CB2 receptor
activation in brain immune cells (Cabral and Griffin-
Thomas, 2009; Ashton and Glass, 2007; Are´valo-Martı´n
et al, 2008), or even with receptor-independent mechanisms
(Hampson et al, 2000; Marsicano et al, 2002)), our and other
Figure 7 CB1 interactions with the antiinflammatory pathway L-PGDS/15d-PGJ2/PPARg. (a) Western blot and densitometric analysis of the enzyme
L-PGDS in prefrontal cortex homogenates of control (CWT), stressed during 4 days (SWT) and stressed + daily ACEA (SWT + ACEA) wild-type mice
and control (CKO) and stressed (SKO) CB1 KO mice. Data are normalized by b-actin (lower band) and are representative of three experiments. *po0.05
vs CWT; #po0.05 vs SWT (one-way ANOVA followed by Newman–Keuls post hoc test). AU, arbitrary units. (b) Antiinflammatory 15d-PGJ2 levels in
prefrontal cortex homogenates of control (CWT), stressed during 4 days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice, and control
(CKO) and stressed (SKO) CB1 KO mice. Data represents the mean± SEM of six mice. *po0.05 vs CWT; #po0.05 vs SWT; &po0.05 vs CKO (one-way
ANOVA followed by Newman–Keuls post hoc test). (c) Western blot and densitometric analysis of the nuclear receptor PPARg in prefrontal cortex
homogenates of control (CWT), stressed during 4 days (SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice, and control (CKO) and
stressed (SKO) CB1 KO mice. Data are normalized by b-actin (lower band), and are representative of three experiments. *po0.05 vs CWT; #po0.05 vs
SWT (one-way ANOVA followed by Newman–Keuls post hoc test). AU, arbitrary units.
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studies revealed a significant role for CB1 as well in
inflammatory/immune responses in animal models of MS
(Are´valo-Martı´n et al, 2003; Pryce et al, 2003; Maresz et al,
2007) and brain ischemia (Ferna´ndez-Lo´pez et al, 2006).
Here, we demonstrated that CB1 activation interacted
with the proinflammatory response elicited by stress at
multiple levels. In the case of cytokines, CB1 activation has
been shown to reduce TNFa and IL-1b synthesis in neurons,
astrocytes, and microglia (Ferna´ndez-Lo´pez et al, 2006;
Maresz et al, 2007; Marchalant et al, 2009). Notably, the
opposite relationship, in which cytokines presumably
upregulate cannabinoid receptor expression, has also
been suggested in some immune/inflammatory scenarios
(Jean-Gilles et al, 2010), stress included (Lee et al, 2006).
Regarding other stress-induced proinflammatory media-
tors, like the key transcription factor NF-kB, our results
coincide with others showing a role for CB1 in NF-kB
regulation in injured mouse brains (Panikashvili et al,
2005); however regulation of NF-kB by cannabinoids has
been commonly related with CB2 in some immune cells
such as macrophages or monocytes (Jeon et al, 1996; Rajesh
et al, 2008); and even with CB1/CB2 receptor-independent
mechanisms, as is the case of cannabidiol in LPS-activated
microglia (Kozela et al, 2010) or 2-arachidonyl glycerol
through PPARg (Rockwell et al, 2006).
Two main NF-kB-dependent enzymatic sources of
oxidative/nitrosative mediators after stress in the brain
are NOS-2 and COX-2. NOS-2 expression is downregulated
by selective CB1 activation in neurons and astrocytes
both in in vitro and in vivo inflammatory-related models
(Ferna´ndez-Lo´pez et al, 2006; Esposito et al, 2006; Sheng
et al, 2005), as it is also reported in our study. However,
cannabinoid–cyclooxygenase interactions may be more
intricate. In our stress model, CB1 regulates the levels of
the presumed COX-2 product PGE2 without altering enzyme
expression. These results suggest possible effects of ACEA
Figure 8 Validation of CB1-mediated ACEA effects. (a) Western blot
and densitometric analysis of the astroglial glutamate transporter EATT-2 in
prefrontal cortex homogenates of control (CWT), stressed during 4 days
(SWT), and stressed + daily ACEA (SWT + ACEA) wild-type mice and
stressed + daliy ACEA (SKO + ACEA) CB1 KO mice. Data are
normalized by b-actin (lower band), and are representative of three
experiments. *po0.05 vs CWT; #po0.05 vs SWT; $po0.05 vs SWT +
ACEA (one-way ANOVA followed by Newman–Keuls post hoc test). AU,
arbitrary units. (b) NOS-2 protein expression analysis by western blot and
densitometric analysis of the band of interest in prefrontal cortex samples
of control (CWT), stressed during 4 days (SWT), and stressed + daily
ACEA (SWT + ACEA) wild-type mice and stressed + daliy ACEA (SKO
+ ACEA) CB1 KO mice. Data are normalized by b-actin (lower band), and
are representative of three experiments. *po0.05 vs CWT; #po0.05 vs
SWT; $po0.05 vs SWT + ACEA (one-way ANOVA followed by
Newman–Keuls post hoc test). AU, arbitrary units. (c) MDA levels
(lipid peroxidation index) in prefrontal cortex homogenates of control
(CWT), stressed during 4 days (SWT), and stressed + daily ACEA (SWT
+ ACEA) wild-type mice and stressed + daily ACEA (SKO + ACEA)
CB1 KO mice. Data represents the mean ± SEM of six mice.
Figure 9 Schematic view of the regulatory role of CB1 on stress-induced
excitotoxicity and neuroinflammatory balance. NMDA, N-methyl-D-asparte
receptor; EAAT-2, excitatory aminoacid transporter-2; CB1, cannabinoid
receptor 1; NF-kB, nuclear factor kappa B; NOS-2, nitric oxide synthase
type II; COX-2, cyclooxygenase type II; L-PGDS, lipocalin prostaglandin
D synthase; 15d-PGJ2, 15d-prostaglandin J2; PPARg, peroxisome prolifera-
tors-activated receptor g; (), inhibition; ( + ), stimulation; ?, alternative
mechanisms. Black, proinflammatory mediators. Grey, antiinflammatory
mediators.
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on the catalytic activity or protein stability of COX-2, or a
possible effect on the activity of tissue-specific prosta-
glandin E2 synthases, which is yet to be explored. Some
authors have reported opposite COX-2/CB1 interactions:
protection afforded by 2-arachidonoylglycerol and THC
by downregulation of COX-2 expression and activity in
cultured neurons, and LPS stimulated J774 macrophages
(Zhang and Chen, 2008; Chang et al, 2001), or THC
neurotoxicity in hippocampal neurons in a mechanism
attributable to COX-2 activity and the concomitant genera-
tion of free radicals (Chan et al, 1998).
Our results show expression changes in the anti-
inflammatory pathway L-PGDS/15d-PGJ2/PPARg after CB1
pharmacological and genetic manipulations; although still
speculative, the involvement of this antiinflammatory
pathway in CB1 neuroprotective effects is an interesting
idea that deserves further investigation. This potential
relationship is especially relevant as some pharmacological
and genetic studies using CB1/CB2 KO mice indicate
possible CB1/CB2 alternative mechanisms of action. PPARs
could be excellent candidates, taking into account
that diverse cannabinoids are potent ligands of PPARs
(O’Sullivan, 2007). Thus, the main endocannabinoids,
anandamide, and 2-arachidonoylglycerol, and also ajulemic
acid, a THC structural analog, have antiinflammatory
properties mediated by PPARg (Sun and Bennett, 2007).
In addition, the endogenous acylethanolamines, oleoyl-
ethanolamide, and palmitoylethanolamide have neuro-
protective effects mediated through PPARa. The possibility
of these related acylethanolamines modulating the stress
response through interaction with PPARa remains unexplored.
Our results show a significant upregulation of L-PGDS/
15d-PGJ2 after ACEA administration. This upregulation
has been also demonstrated after the administration of
ajulemic acid to human synovial cells (Stebulis et al,
2008), inducing an antiinflammatory profile of eicosanoids.
PPARg regulation is not yet completely understood, but
one of the main mechanisms may be ligand availability
(Daynes and Jones, 2002). This kind of regulation could
be important in our stress model because we also found
increased 15d-PGJ2 levels after ACEA administration. Other
authors have proposed alternative mechanisms by which
cannabinoids can potentially lead to PPARs activation. For
example, CB1 binding could stimulate MAPK pathways, as
it occurs in other scenarios (Le´picier et al, 2006), which
regulates PPARg transcriptional activity by direct phos-
phorylation on serine residues (Burns and Vanden Heuvel,
2007).
In contrast to ACEA neuroprotective effects in stress
conditions, we and others have showed a dysregulated HPA
axis activity in basal and after stress exposure in CB1 KO
mice (Barna et al, 2004; Cota, 2008; Aso et al, 2008). In
addition, a status of excessive excitotoxicity and neuroin-
flammation is also presented, increasing their susceptibility
to experience damage and even cellular death. Similarly, in
an animal model of Parkinson’s disease, other authors have
also found an increased vulnerability to 6-hydroxy-
dopamine lesion in CB1 KO mice, presenting a higher
index of lipid peroxidation and NOS-2 expression in
selected brain areas (Pe´rez-Rial et al, 2009).
In addition to HPA axis dysregulation, chronic excito-
toxicity, and neuroinflammation, CB1 KO mice present
defective adult neurogenesis (Jin et al, 2004), increased
anxiety (Urigu¨en et al, 2004; Mikics et al, 2009), and
deficiency in neuronal plasticity by decreasing BDNF levels
in the hippocampus (Aso et al, 2008), suggesting a possible
role of CB1 in the pathophysiology of depression and its
pharmacological manipulation as a potential therapeutic
strategy.
In summary, the multifaceted neuroprotective effects
described here suggest that CB1 activation is an attractive
therapeutic strategy against diverse neuropsychiatric patho-
logies with HPA axis dysregulation and an excitotoxic/
neuroinflammatory component in their pathophysiology.
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